Targeted Fusions Effective for Higher Response Rates and Longer PFS
Results in this study suggested that targeting fusions led to considerably high response rates and longer progression-free survival.
Related Articles
Anti-BCMA and Anti-GPRC5D BiTEs Show Similar Efficacy in Multiple Myeloma
A real-world analysis of teclistamab, elranatamab, and talquetamab showed comparable outcomes in relapsed or refractory multiple myeloma.
Breast Cancer | Oncology News & Insights | CancerNetwork
The breast cancer section is a comprehensive resource for clinical news and expert insights on breast cancer. Read more at CancerNetwork.
The Evolving Landscape of CDK4/6 Inhibitors in Adjuvant HR+/HER2- Breast Cancer
Heather McArthur, MD, spoke about the use of CDK4/6 inhibitors in the adjuvant setting for patients with HR+/HER2– breast cancer.
FDA Grants Orphan Drug Designation to Quemliclustat in Pancreatic Cancer
Quemliclustat plus gemcitabine and nab-paclitaxel chemotherapy outperformed median OS benchmarks in patients with metastatic PDAC.
FDA Clears AI-Based Visualization Software for Surgical Breast Cancer Care
Use of TumorSight Viz may support improved consistency, precision, and efficiency in breast cancer surgery.
SRS Lessens Rate of Neurologic Death vs WBRT in SCLC and Brain Metastases
Results from a phase 2 study showed a median OS of 10.2 months in all patients with small cell lung cancer who received stereotactic radiation…
Encorafenib Combo Earns Chinese Approval in BRAF V600E+ Metastatic CRC
Data from the phase 3 BEACON CRC trial support the approval of encorafenib plus cetuximab for this colorectal cancer population in China.
Botensilimab/Balstilimab Elicits Sustained Efficacy in MSS Metastatic CRC
The FDA has waived the need for a botensilimab monotherapy arm in the phase 3 BATTMAN trial evaluating the combination in MSS metastatic colorectal cancer.
HTMC0435 Plus Chemotherapy Yields Responses in Relapsed ES-SCLC
HTMC0435 plus temozolomide led to an ORR of 24.5%, with a median OS of 12.0 months, in patients with platinum-sensitive and platinum-resistant small cell lung…
Pembrolizumab/Vorinostat Has Promising Activity in Squamous Cell Carcinoma
Investigators of the phase 2 PEVOsq trial identify PD-L1 positivity and HPV positivity as predictive biomarkers of response to the pembrolizumab regimen.